The specificities of SHOX2, RASSF1A and LungMe® methylation in diagnosing lung adenocarcinoma from benign lesions were 97.1% (33/34), 97.1% (33/34) and 94.1% (32/34) (Table 2). This evidence concerns the gene RASSF1 and lung adenocarcinoma.